drugset / Trial / NCT07221838

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

NCT07221838

Phase 4 Recruiting 75 enrolled Alexion Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.

Timeline

Start
2026-03-04
Primary completion
2027-08-27
Completion
2027-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Prednisolone Other / unclassified Oral
Subject Prednisone Other / unclassified Oral
Background Ravulizumab Monoclonal antibody Intravenous